Why One-Size-Fits-All Clinical Timeline Benchmarks Fail Portfolio Planners
Clinical development executives, venture capital diligence teams, and academic trial offices frequently benchmark protocol cycle times against an aggregate cross-industry median (693 days and 71.0 actual participants across all 54,890 protocols in Protocol Ledger). Yet disaggregating the 2018 to 2026 empirical cohort across ten canonical MeSH and condition-mapped therapeutic areas demonstrates more than a 2.9x spread in completed study duration and a 3.5x spread in median sample size.
Oncology and Hematology (ONC) accounts for 22,601 protocols (41.17% of global Phase II and Phase III interventional volume and 53.57% of all currently active trial load at 12,884 active protocols). Despite recruiting the smallest median cohort of any therapeutic group (43.0 actual patients, driven by biomarker-selected tumor mutations, CAR-T cell therapies, and antibody-drug conjugates), completed oncology trials require a median of 1,269 calendar days (3.47 years) to reach completion due to progression-free survival (PFS), overall survival (OS), and narrow molecular screening funnels.
| Code | Therapeutic Area | Protocols | Active Load | Completed | Stopped | Median N | Median Days | Site Discl. |
|---|---|---|---|---|---|---|---|---|
| ONC | Oncology and Hematology | 22,601 | 12,884 | 3,040 | 2,734 | 43.0 | 1,269.0 | 89.7% |
| OTH | Rare Genetic, Women's Health, and Other | 10,777 | 3,944 | 3,957 | 1,190 | 60.0 | 572.0 | 81.6% |
| INF | Infectious Disease and Vaccines | 5,536 | 1,149 | 2,510 | 933 | 152.0 | 456.0 | 82.4% |
| NEU | Neurology, Psychiatry, and Pain | 4,809 | 1,909 | 1,763 | 628 | 84.0 | 714.0 | 86.4% |
| IMM | Immunology, Rheumatology, and Dermatology | 3,376 | 1,326 | 1,249 | 466 | 119.0 | 690.0 | 78.5% |
| END | Endocrinology, Obesity, and Metabolic | 2,382 | 857 | 1,032 | 219 | 113.0 | 616.0 | 86.3% |
| CVM | Cardiovascular and Thrombosis | 2,184 | 831 | 799 | 245 | 102.5 | 695.0 | 75.2% |
| RSP | Respiratory and Pulmonary | 1,201 | 435 | 506 | 146 | 91.0 | 651.0 | 56.6% |
| GAS | Gastroenterology, Hepatology, and Renal | 1,088 | 422 | 396 | 140 | 76.0 | 662.5 | 71.5% |
| OPH | Ophthalmology and Sensory | 936 | 295 | 438 | 95 | 106.0 | 426.5 | 81.7% |
Comparing Oncology, CNS, Rare Disease, and Cardiometabolic Attrition Profiles
Look closely at the divergence between raw overall termination percentages and closed-cohort termination ratios (stopped / (completed + stopped)) in Table 2. Because 12,884 of Oncology's 22,601 studies remain active, its raw termination rate appears moderate at 12.10%. However, among the 5,774 Oncology studies that have closed since 2018, 47.35% (2,734 vs 3,040) terminated prematurely, with 746 citing slow accrual and 280 citing dose-limiting toxicity or adverse events.
Neurology, Rare Disease, and the GLP-1 / Cardiometabolic Execution Advantage
Other major therapeutic pillars exhibit markedly different operational trade-offs:
- Neurology, Psychiatry, and Pain (
NEU, 4,809 protocols): Enrolls nearly double Oncology's median sample size (84.0subjects) over714median days, posting a13.06%overall stop rate (26.27% of closed studies) and one of the highest futility shares among stopped studies (54 futility stops, reflecting high placebo-response variance in psychiatric and pain endpoints and slow neurodegeneration modification). - Endocrinology, Obesity, and Metabolic (
END, 2,382 protocols) & Cardiovascular (CVM, 2,184 protocols): Endocrinology achieves the lowest overall termination rate in biopharma at9.19%(17.51% of closed protocols) alongside brisk616-day completion medians and113.0median enrollment, buoyed by rapid patient demand in incretin/GLP-1 obesity, MASH, and diabetes trials and objective biomarker endpoints (HbA1c, percent body-weight loss). Cardiovascular programs enroll102.5median subjects over695days with an11.22%overall stop rate. - Rare Genetic, Women's Health, and Other (
OTH, 10,777 protocols): Completes faster (572median days,60.0median enrollment) with a23.12%closed-cohort stop rate, though monogenic rare-disease programs remain sensitive to geographic registry reach (287 slow-accrual closures). - Infectious Disease and Vaccines (
INF, 5,536 protocols): Posts the highest overall stop rate (16.85%) alongside the largest median enrollment (152.0subjects) and shortest duration (456days), capturing acute COVID-19 and seasonal viral trials whose incidence waves subsided mid-enrollment.
| Therapeutic Area | Overall Stop % | Closed Stop % | Slow Accrual | Safety Stops | Futility Stops | CA Protocols | CA Share % |
|---|---|---|---|---|---|---|---|
| Oncology and Hematology | 12.10% | 47.35% | 746 | 280 | 126 | 3,297 | 14.6% |
| Rare Genetic, Women's Health, and Other | 11.04% | 23.12% | 287 | 125 | 63 | 1,737 | 16.1% |
| Infectious Disease and Vaccines | 16.85% | 27.10% | 228 | 99 | 61 | 832 | 15.0% |
| Neurology, Psychiatry, and Pain | 13.06% | 26.27% | 137 | 68 | 54 | 1,121 | 23.3% |
| Immunology, Rheumatology, and Dermatology | 13.80% | 27.17% | 65 | 70 | 45 | 1,099 | 32.6% |
| Endocrinology, Obesity, and Metabolic | 9.19% | 17.51% | 40 | 25 | 10 | 658 | 27.6% |
| Cardiovascular and Thrombosis | 11.22% | 23.47% | 58 | 16 | 19 | 403 | 18.5% |
| Respiratory and Pulmonary | 12.16% | 22.39% | 22 | 26 | 12 | 320 | 26.6% |
| Gastroenterology, Hepatology, and Renal | 12.87% | 26.12% | 33 | 15 | 13 | 262 | 24.1% |
| Ophthalmology and Sensory | 10.15% | 17.82% | 13 | 11 | 13 | 317 | 33.9% |
California's Disproportionate Immunology, Ophthalmology, and Neuro-Oncology Footprint
Geographic concentration across Table 2 also highlights where U.S. translational capacity clusters. While California hosts 18.30% of the global Phase II/III cohort overall (10,046 protocols, representing 46.92% of all 21,410 U.S.-site studies), California's share surges to 33.9% in Ophthalmology and Sensory trials (317 of 936 studies, anchored by Byers Eye Institute at Stanford, UCSF Proctor Foundation, Doheny/UCLA Stein, and Shiley Eye Institute at UC San Diego), 32.6% in Immunology, Rheumatology, and Dermatology (1,099 of 3,376 studies), and 27.6% in Endocrinology and Obesity (658 of 2,382 studies). Selecting sites outside saturated coastal hubs requires calibrating indication-specific clinic infrastructure rather than assuming uniform geographic availability.
Methodology and Multi-Condition Classification Notes
Each protocol in the Sponsor & Site Directory is assigned deterministically to a single primary therapeutic area using hierarchical MeSH and condition-keyword rules so cohort counts sum cleanly to 54,890 without double-counting basket trials. Completed duration days measure elapsed time from registered StartDate to CompletionDate after quarantining 56 placeholder completion horizons exceeding calendar year 2040.